Hostname: page-component-7c8c6479df-27gpq Total loading time: 0 Render date: 2024-03-28T10:02:39.292Z Has data issue: false hasContentIssue false

Audit of antipsychotic prescribing in dementia

Published online by Cambridge University Press:  02 January 2018

Tom MacEwan
Affiliation:
Royal Cornhill Hospital, Aberdeen AB25 2ZH, Scotland, email: tom.macewan@gpct.grampian.scot.nhs.uk
Elizabeth Turner
Affiliation:
University of Aberdeen
Gillian Murray
Affiliation:
Royal Cornhill Hospital, Aberdeen
Rights & Permissions [Opens in a new window]

Abstract

Type
Columns
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 2007

Soyinka & Lawley (Psychiatric Bulletin, May 2007, 31, 176-178) report an audit of a crucial treatment in dementia. The finding that 54% of patients received an antipsychotic accords with an audit we conducted in which 49% of patients with behavioural and psychological symptoms of dementia received such treatment. These patients were living in care homes and were referred by general practitioners. We disagree that this represents a ‘ concerning trend of “medicalising”’ such symptoms. These patients are probably at the severe end of a spectrum so it is not surprising that many require antipsychotics. We feel that many patients do benefit from these drugs. Even CATIE-AD (Reference SCHNEIDER, TARIOT and DAGERMANSchneider et al, 2006) report effectiveness of antipsychotics but suggest restriction to patients with minimal side-effects and where benefit is observed.

We disagree with the assumption that findings can be generalised across the country; 50% of patients in the report received typical antipsychotics compared with only 12% in our audit. We note that the National Institute for Health and Clinical Excellence does not distinguish between antipsychotic subtypes (National Institute for Health and Clinical Excellence, 2006) and we wonder if this reflects the growing realisation, referred to by Soyinka & Lawley, that cerebrovascular risk might be shared by all antipsychotics, not just the atypicals.

We have a designated community psychiatric nursing service for care homes, which improves quality of care with targeted antipsychotic use and prompt follow-up and liaison. All patients in our audit had a clear indication for treatment and 94% were reviewed within 3 months. We should use antipsychotic drugs when required to alleviate patient suffering and agree that documented review of patients on antipsychotic drugs is important.

References

SCHNEIDER, L. S., TARIOT, P. N., DAGERMAN, K. S., et al (2006) Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine, 355, 15251538.CrossRefGoogle ScholarPubMed
National Institute for Health and Clinical Excellence (2006) Dementia. Supporting People with Dementia and Their Carers in Health and Social Care. NICE. http://www.nice.org.uk/CG042 Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.